Discussion on Sparkle Study Enrollment, Endpoints, FDA Designation, and Market Potential for Novel Drug|Magnus Corfitzen, CEO, Ascelia Pharma AB. 00:10:00

Share On Facebook Share On Twitter

The CEO of a pharmaceutical company provides insights into the latest developments regarding the Sparkle study, including enrollment status, primary and secondary endpoints, FDA orphan drug designation, and market potential for the drug under development.

Recent Videos